Diary - News All news Early Immune Effect of SCIB1 Cancer Vaccine Observed in Blood by ImmunTraCkeR® Companion Diagnostic

Early Immune Effect of SCIB1 Cancer Vaccine Observed in Blood by ImmunTraCkeR® Companion Diagnostic

ImmunTraCkeR® to be incorporated into SCIB1’s upcoming Phase II checkpoint inhibitor combination clinical trial
ImmunTraCkeR® represents potential companion diagnostic for early detection of patient response to SCIB1 immunotherapy

Scancell Holdings plc (‘Scancell’ LSE:AIM SCLP), the developer of novel immunotherapies for the treatment of cancer, and immune companion diagnostic developer ImmunID, today released data showing patient immunologic response to cancer vaccine SCIB1 can be demonstrated through monitoring changes in the diversity of T cells found in the blood.

Read the press release

To go further...

See ImmunID profil

Headlines

Our members

Lys Therapeutics and Inserm Transfert sign a three-year agreement

March 4^th, 2022

VirexpR annonce l’entrée stratégique à son capital du Groupe TERA, acteur majeur de l’analyse, de la mesure et de la valorisation en temps réel de la qualité de l’air

April 28^th, 2022

Nosopharm signs partnership with INRAE and University of Montpellier to develop new anti-infectives

March 15^th, 2022

All news